PD-L1 Expression in Pituitary Neuroendocrine Tumors/Pituitary Adenomas
Published 2023 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
PD-L1 Expression in Pituitary Neuroendocrine Tumors/Pituitary Adenomas
Authors
Keywords
-
Journal
Cancers
Volume 15, Issue 18, Pages 4471
Publisher
MDPI AG
Online
2023-09-08
DOI
10.3390/cancers15184471
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- PD-L1 and tumor-infiltrating CD8+ lymphocytes are correlated with clinical characteristics in pediatric and adolescent pituitary adenomas
- (2023) Mengwu Shi et al. Frontiers in Endocrinology
- Overview of the 2022 WHO Classification of Pituitary Tumors
- (2022) Sylvia L. Asa et al. ENDOCRINE PATHOLOGY
- Clinical Biology of the Pituitary Adenoma
- (2022) Shlomo Melmed et al. ENDOCRINE REVIEWS
- Real-life efficacy and predictors of response to immunotherapy in pituitary tumors: a cohort study
- (2022) Mirela Diana Ilie et al. EUROPEAN JOURNAL OF ENDOCRINOLOGY
- PD-L1 Is Preferentially Expressed in PIT-1 Positive Pituitary Neuroendocrine Tumours
- (2021) John Turchini et al. ENDOCRINE PATHOLOGY
- Aggressive pituitary neuroendocrine tumors: current practices, controversies, and perspectives, on behalf of the EANS skull base section
- (2021) Sam Ng et al. ACTA NEUROCHIRURGICA
- Pituitary neuroendocrine tumors: a model for neuroendocrine tumor classification
- (2021) Sylvia L. Asa et al. MODERN PATHOLOGY
- A review of cancer immunotherapy toxicity
- (2020) Lucy Boyce Kennedy et al. CA-A CANCER JOURNAL FOR CLINICIANS
- MSH6/2 and PD-L1 Expressions Are Associated with Tumor Growth and Invasiveness in Silent Pituitary Adenoma Subtypes
- (2020) Shinsuke Uraki et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Genomic and molecular characterization of pituitary adenoma pathogenesis: review and translational opportunities
- (2020) Mazin Elsarrag et al. Neurosurgical Focus
- Primary and Ipilimumab-induced Hypophysitis: A Single-center Case Series
- (2020) Paul Atkins et al. ENDOCRINE RESEARCH
- Analysis of Cyclooxygenase 2, Programmed Cell Death Ligand 1, and Arginase 1 Expression in Human Pituitary Adenoma
- (2020) Guodong Zhao et al. World Neurosurgery
- The Progress of Immunotherapy in Refractory Pituitary Adenomas and Pituitary Carcinomas
- (2020) Congxin Dai et al. Frontiers in Endocrinology
- CD8 T Cell Exhaustion During Chronic Viral Infection and Cancer
- (2019) Laura M. McLane et al. Annual Review of Immunology
- Non-functioning pituitary adenomas: indications for pituitary surgery and post-surgical management
- (2019) Daniela Esposito et al. Pituitary
- Analysis of Tumor Angiogenesis and Immune Microenvironment in Non-Functional Pituitary Endocrine Tumors
- (2019) Mizuto Sato et al. Journal of Clinical Medicine
- Targeting PD-L1 initiates effective anti-tumor immunity in a murine model of Cushing's Disease
- (2019) Hanna R Kemeny et al. CLINICAL CANCER RESEARCH
- Definition and diagnosis of aggressive pituitary tumors
- (2019) Leandro Kasuki et al. REVIEWS IN ENDOCRINE & METABOLIC DISORDERS
- Combined modalities of surgery, radiotherapy, radiosurgery and chemotherapy for invasive pituitary carcinoma
- (2018) Constantin Tuleasca et al. ANNALES D ENDOCRINOLOGIE
- Treatment of aggressive pituitary tumours and carcinomas: results of a European Society of Endocrinology (ESE) survey 2016
- (2018) Ann McCormack et al. EUROPEAN JOURNAL OF ENDOCRINOLOGY
- The expression profile of PD-L1 and CD8+ lymphocyte in pituitary adenomas indicating for immunotherapy
- (2018) Peng-fei Wang et al. JOURNAL OF NEURO-ONCOLOGY
- Cancer immunotherapy using checkpoint blockade
- (2018) Antoni Ribas et al. SCIENCE
- Marked response of a hypermutated adrenocorticotropic hormone-secreting pituitary carcinoma to ipilimumab and nivolumab
- (2018) Andrew L Lin et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Differential expression of PD-L1 and IDO1 in association with the immune microenvironment in resected lung adenocarcinomas
- (2018) M. Lisa Zhang et al. MODERN PATHOLOGY
- From pituitary adenoma to pituitary neuroendocrine tumor (PitNET): an International Pituitary Pathology Club proposal
- (2017) S L Asa et al. ENDOCRINE-RELATED CANCER
- European Society of Endocrinology Clinical Practice Guidelines for the management of aggressive pituitary tumours and carcinomas
- (2017) Gerald Raverot et al. EUROPEAN JOURNAL OF ENDOCRINOLOGY
- Diagnosis and Treatment of Pituitary Adenomas
- (2017) Mark E. Molitch JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Avelumab, an Anti–Programmed Death-Ligand 1 Antibody, In Patients With Refractory Metastatic Urothelial Carcinoma: Results From a Multicenter, Phase Ib Study
- (2017) Andrea B. Apolo et al. JOURNAL OF CLINICAL ONCOLOGY
- PD-1 expression by tumour-associated macrophages inhibits phagocytosis and tumour immunity
- (2017) Sydney R. Gordon et al. NATURE
- PD-L1 up-regulation in melanoma increases disease aggressiveness and is mediated through miR-17-5p
- (2017) Valentina Audrito et al. Oncotarget
- Coinhibitory Pathways in Immunotherapy for Cancer
- (2016) Susanne H. Baumeister et al. Annual Review of Immunology
- Predictive biomarkers for checkpoint inhibitor-based immunotherapy
- (2016) Geoffrey T Gibney et al. LANCET ONCOLOGY
- Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a multicentre, single-group, open-label, phase 2 trial
- (2016) Howard L Kaufman et al. LANCET ONCOLOGY
- Atypical pituitary adenomas: clinical characteristics and role of ki-67 and p53 in prognostic and therapeutic evaluation. A series of 50 patients
- (2016) Marialaura Del Basso De Caro et al. NEUROSURGICAL REVIEW
- Increased expression of programmed death ligand 1 (PD-L1) in human pituitary tumors
- (2016) Yu Mei et al. Oncotarget
- Predictive biomarkers in PD-1/PD-L1 checkpoint blockade immunotherapy
- (2015) Xiangjiao Meng et al. CANCER TREATMENT REVIEWS
- Invasion of the cavernous sinus space in pituitary adenomas: endoscopic verification and its correlation with an MRI-based classification
- (2015) Alexander S. G. Micko et al. JOURNAL OF NEUROSURGERY
- Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer
- (2015) Julie Brahmer et al. NEW ENGLAND JOURNAL OF MEDICINE
- PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma
- (2015) Stephen M. Ansell et al. NEW ENGLAND JOURNAL OF MEDICINE
- Immunotherapy and hypophysitis: clinical presentation, treatment, and biologic insights
- (2015) Alexander Faje Pituitary
- Invasive adenoma and pituitary carcinoma: a SEER database analysis
- (2014) Tara M. Hansen et al. NEUROSURGICAL REVIEW
- A new prognostic clinicopathological classification of pituitary adenomas: a multicentric case–control study of 410 patients with 8 years post-operative follow-up
- (2013) Jacqueline Trouillas et al. ACTA NEUROPATHOLOGICA
- Classification accuracy and cut point selection
- (2012) Xinhua Liu STATISTICS IN MEDICINE
- Aggressive pituitary tumours: the role of temozolomide and the assessment of MGMT status
- (2011) Ann I. McCormack et al. EUROPEAN JOURNAL OF CLINICAL INVESTIGATION
- Pituitary Incidentaloma: An Endocrine Society Clinical Practice Guideline
- (2011) Pamela U. Freda et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Cancer immunotherapy comes of age
- (2011) Ira Mellman et al. NATURE
- Pathogenesis of pituitary tumors
- (2011) Shlomo Melmed Nature Reviews Endocrinology
- Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma
- (2011) Caroline Robert et al. NEW ENGLAND JOURNAL OF MEDICINE
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started